Squamous Cell Carcinoma of the Head and Neck – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of SCCHN for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.
SCCHN forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s SCCHN forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of SCCHN and the number of new diagnoses of SCCHN?
- Of all people diagnosed with SCCHN, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SCCHN over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following SCCHN subpopulations:
- Diagnosed incident cases
- Diagnosed prevalent cases
- Diagnosed metastatic and non metastatic incident cases
- Diagnosed metastatic recurrent incident cases
- Diagnosed oral cavity incident cases
- Diagnosed HPV +ve oropharynx incident cases
- Diagnosed HPV-ve oropharynx incident cases
- Diagnosed nasopharynx incident cases
- Diagnosed hypopharynx incident cases
- Diagnosed larynx incident cases
- Diagnosed other primary sites incident cases
- Diagnosed drug-treatable populations
- Diagnosed drug-treated populations
Note: Coverage may vary by country
